Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares conducted on November 14, 2025. The filing was submitted on November 17, 2025. The transaction was executed by BNP Paribas SA acting as the broker under a non-discretionary agreement announced on September 30, 2025.
Key Financial Metrics
The filing details a specific share repurchase event rather than comprehensive financial results. Key metrics for this transaction include:
- Shares Purchased: 170,000 ordinary shares of 31½ pence each.
- Price Range: Lowest price paid was 1,777.00p; highest price paid was 1,807.50p.
- Average Price: Volume-weighted average price (VWAP) was 1,788.23p.
- Treasury Holdings: Following this purchase, GSK holds 256,464,844 ordinary shares in treasury.
- Shares in Issue: 4,058,966,266 ordinary shares (excluding treasury shares).
- Voting Rights: Treasury shares represent 6.32% of total voting rights.
Material Changes
This transaction is part of an ongoing buyback programme. Since the programme's announcement on September 30, 2025, the company has purchased a total of 9,000,000 ordinary shares. The filing does not provide comparative financial data (revenue, profit, or cash flow) for the period, as it is a regulatory disclosure of a capital transaction.
Guidance, Outlook, and Risks
The filing contains a standard cautionary statement regarding forward-looking statements. GSK notes that projections are subject to risks and uncertainties that may cause actual results to differ materially. Specific risks are referenced in the "Risk Factors" section of the 2024 Annual Report on Form 20-F and the Q3 Results for 2025. No new guidance or management commentary regarding operational outlook is provided in this specific document.
Investor Verification Checklist
- Verify the total cumulative buyback volume since September 30, 2025 (stated as 9,000,000 shares).
- Confirm the current percentage of voting rights held in treasury (stated as 6.32%).
- Review the referenced 2024 Form 20-F and Q3 2025 results for detailed risk factors and operational performance.
- Check the remaining authorization under the existing buyback programme to assess future capital return capacity.